Hemwong Nalinee, Phokaew Chureerat, Srichomthong Chalurmpon, Tongkobpetch Siraprapa, Srilanchakon Khomsak, Supornsilchai Vichit, Suphapeetiporn Kanya, Porntaveetus Thantrira, Shotelersuk Vorasuk
Medical Sciences Program, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Center of Excellence for Regenerative Dentistry, Faculty of Dentistry, Chulalongkorn University, Bangkok, 10330, Thailand.
J Adv Res. 2019 Oct 21;21:121-127. doi: 10.1016/j.jare.2019.10.006. eCollection 2020 Jan.
Genetic disorders have been shown to co-occur in individual patient. A Thai boy with features of osteogenesis imperfecta (OI) and combined pituitary hormone deficiency (CPHD) was identified. The causative mutations were investigated by whole exome and Sanger sequencing. Pathogenicity and pathomechanism of the variants were studied by luciferase assay. The proband was found to harbor a novel heterozygous missense mutation, c.1531G > T (p.G511C), in leading to OI and a heterozygous missense variant, c.364C > T (p.R122W), in . The p.R122W has never been reported to cause CPHD. The variant was predicted to be deleterious and found in the highly conserved LIM2 domain of LHX4. The luciferase assays revealed that the p.R122W was unable to activate , , and promoters, validating its pathogenic effect in CPHD. Moreover, the variant did not alter the function of wild-type , indicating its hypomorphic pathomechanism. In conclusion, the novel heterozygous p.G511C mutation in and the heterozygous pathogenic p.R122W mutation in were demonstrated in a patient with OI and CPHD. This study proposes that the mutations in two different genes should be sought in the patients with clinical features unable to be explained by a mutation in one gene.
遗传疾病已被证明在个体患者中同时出现。一名具有成骨不全(OI)特征和联合垂体激素缺乏(CPHD)的泰国男孩被确诊。通过全外显子测序和桑格测序对致病突变进行了研究。通过荧光素酶测定法研究了变异体的致病性和发病机制。先证者被发现携带一个新的杂合错义突变,c.1531G>T(p.G511C),导致OI,以及一个杂合错义变异,c.364C>T(p.R122W),位于。p.R122W从未被报道可导致CPHD。该变异体被预测为有害的,并在LHX4的高度保守的LIM2结构域中发现。荧光素酶测定显示,p.R122W无法激活、和启动子,证实了其在CPHD中的致病作用。此外,该变异体并未改变野生型的功能,表明其致病机制为亚效性。总之,在一名患有OI和CPHD的患者中发现了新的杂合p.G511C突变和杂合致病性p.R122W突变。本研究建议,对于临床特征无法用一个基因的突变来解释的患者,应寻找两个不同基因中的突变。